3DCardio is a Digital Platform for the 3D growth of engineered heart tissue, developed with support from the European Union-funded NextGenerationEU National Recovery and Resilience Plan (NRP), M4C2 - investment 1.5.
This success is the result of an extraordinary collaboration between IRS Srl and ICGEB .
At the heart of the project is the development of a sensorized device for creating engineered 3D cardiac tissues. These tissues represent a breakthrough in disease modeling, drug and therapy testing, and regenerative medicine applications.Cardiovascular disease is still the leading cause of death worldwide. Engineering cardiac tissues offers the opportunity to create models to better understand these diseases and provide more effective treatments for cardiomyopathies.
With 3DCardio, we will develop an advanced digital platform for the preparation of engineered 3D cardiac tissue. IRS has already built digitized systems to monitor and control cell growth and devices to automate the decellularization of cardiac tissue, which will be critical in our project.
The ICGEB will contribute its expertise in tissue engineering using induced pluripotent stem cells, ensuring a state-of-the-art growth process and digitization of engineered 3D tissue, as well as testing innovative methodologies from decellularized matrices.The synergy between the expertise of IRS and ICGEB will lead to the creation of a digitized platform for the production of engineered 3D cardiac tissue, paving the way for new medical advances in the diagnosis and treatment of cardiovascular disease.*The video shows a live recording of an engineered cardiac tissue directly from the platform now being researched.
